Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amiselimod - Tanabe Pharma Corporation/Salix Pharmaceuticals

Next Previous
Drug Profile

Amiselimod - Tanabe Pharma Corporation/Salix Pharmaceuticals

Alternative Names: MT-1303; SLX-G1018

Latest Information Update: 06 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Bausch Health Companies; Mitsubishi Tanabe Pharma Corporation; Salix Pharmaceuticals
  • Class Anti-inflammatories; Antipsoriatics; Propylene glycols; Small molecules
  • Mechanism of Action Immunosuppressants; Sphingosine 1 phosphate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Discontinued Autoimmune disorders; Crohn's disease; Inflammation; Inflammatory bowel diseases; Multiple sclerosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Plaque psoriasis; Systemic lupus erythematosus

Most Recent Events

  • 01 Dec 2025 Mitsubishi Tanabe Pharma Corporation is now called Tanabe Pharma Corporation
  • 08 Nov 2024 Bausch Health Americas completes phase II clinical trials in Ulcerative colitis in Taiwan, Ukraine, South Korea, South Korea, Slovakia, Russia, Serbia, Poland, Japan, Australia, Belarus, Bulgaria, Estonia, Czech Republic, Germany, Hungary, Georgia, Italy, Moldova, Moldova and US (PO) (NCT04857112)
  • 17 Aug 2023 Discontinued - Phase-I for Multiple sclerosis in Japan (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top